Grant: TG: Interv. Trial in Inflam. Chronic Cond. -CIHR HIV/AIDS/STBBI Res. Initiative

At present, HIV is a chronic manageable disease, but it remains incurable. In this context, Aging well with HIV is a public health priority. The study population of this research project are people living with HIV with undetectable viral load, and the overarching goal of this program is to close the prognostic gap for these people, so that they may have an optimal health related quality of life. Recognizing the complexity of aging with HIV, our study team includes researchers from multiples domains of expertise, including general internal medicine, microbiology and immunology, cardiology, diagnostic radiology, virology, immunology, epidemiology and trial experts, as well as a team of partcipants with diverse life experiences. Briefly, this study is a randomized, placebo controlled trial of fostemsavir to reduce inflammation in people living with HIV with undetectable viral load but detectable levels of HIV env protein subunit gp120 in plasma. It will establish whether treatment with fostemsavir can reduce inflammation and comorbidities such as cardiovascular disease in this population. At present, no intervention has been shown effective to reduce the risk of cardiovascular disease that is secondary to the chronic inflammation present in people living with HIV.